Home/Dependencies/Products/Anti-TB APIs (Isoniazid, Rifampicin)

Anti-TB APIs (Isoniazid, Rifampicin)

High dependencyBuild-nowPharmaceuticals & APIsReasoned estimateHS 2933.39
$0.10 bnAnnual import
25%Indian capability
5,300Supplier concentration (HHI)
₹800 crTo localise

Why India imports it. China controls KSM for isoniazid; India has TB programme scale.

Why it matters. India has 27% of global TB cases.

Can India localise it? Yes - 3-4 years.

Where it comes from. China (70%), India (25%), Italy (5%).

Scorecard

The ten indices

CMDI 67.75Dependency
LPI 60Localisation potential
IAI 66.25Investment attractiveness
SRI 69Supply risk
SCI 50Supply-chain complexity
TRI 40.75Technology readiness
IMI 66.5Industrial multiplier
NSRI 59.75National-security relevance
EPI 65.25Export potential
ICGI 59.75Capability gap
Who makes it

Manufacturers

In India

Lupin LtdMacleods Pharmaceuticals

Global leaders

Huaheng ChemicalChangzhou Pharma

On the ground

Localisation projects

Intelligence

Related signals

Sources

Primary references

Confidence: Reasoned estimate. Reasoned estimate. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).